Uncovering an insidious insulinoma with glucagon-like peptide-1 receptor agonist: a case report and review of the literature
European Journal of Case Reports in Internal Medicine · 19.11.2026
DOI: 10.12890/2026_007447 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Journal of Case Reports in Internal Medicine, online erschienen am 19.11.2026. Verfasst von Kai Xiong Lim und 3 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Insulinoma is a rare neuroendocrine tumour that secretes insulin resulting in hypoglycaemia. The initial diagnosis of insulinoma can be challenging in view of the intermittent and non-specific symptoms. Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly being prescribed for the treatment of diabetes mellitus and obesity. We discuss a case of how a GLP-1 receptor agonist unmasked a previously undiagnosed insulinoma. Case description: A 48-year-old woman with class III obesity was started on subcutaneous semaglutide, a GLP-1 receptor agonist, for weight management. After the initiation of semaglutide, she started having recurrent symptoms of hypoglycaemia that was initially unevaluated. The symptoms worsened when the patient developed an episode of gastroenteritis, which resulted in her fainting. Further work up of the hypoglycaemia revealed endogenous hyperinsulinaemia, with imaging confirming the diagnosis of an insulinoma. Insulinoma is known to overexpress GLP-1 receptors that bind to GLP-1 receptor agonists. Coupled with the caloric restriction from GLP-1 receptor agonist, exacerbated by acute gastroenteritis, this resulted in the patient presenting with recurrent symptomatic hypoglycaemia.
Conclusion
GLP-1 receptor agonists can unmask previously asymptomatic insidious insulinomas. Since GLP-1 receptor agonist alone should rarely cause hypoglycaemia, a thorough evaluation is required to determine the underlying cause of this patient’s recurrent hypoglycaemia. This is especially important with the increasing usage of GLP-1 receptor agonists.
Zitieren
APA
Lim, K. X., Tay, S. B., Cheong, Y. L. B., & Wee, Z. (2026). Uncovering an insidious insulinoma with glucagon-like peptide-1 receptor agonist: a case report and review of the literature. European Journal of Case Reports in Internal Medicine. https://doi.org/10.12890/2026_007447
Vancouver
Lim KX, Tay SB, Cheong YLB, Wee Z. Uncovering an insidious insulinoma with glucagon-like peptide-1 receptor agonist: a case report and review of the literature. European Journal of Case Reports in Internal Medicine. 2026. doi:10.12890/2026_007447
BibTeX
@article{Lim2026,
author = {Lim, Kai Xiong and Tay, Sok Boon and Cheong, Yi Loong Benny and Wee, Zongwen},
title = {Uncovering an insidious insulinoma with glucagon-like peptide-1 receptor agonist: a case report and review of the literature},
journal = {European Journal of Case Reports in Internal Medicine},
year = {2026},
doi = {10.12890/2026_007447}
}
EUVIMED